Autopsy report · NCT00271011
A Study of Mitomycin C, Irinotecan, and Cetuximab
Cause of deathStaffing, sites or logistics, also safety
“The study was discontinued due to the death of a co-investigator and a second co-investigator leaving the institution.”
Life of this trial
- Ran for about 3 years 7 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 5 years after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Michigan Rogel Cancer Center
- Sponsor type
- University, hospital or other
- Conditions
- Colorectal Cancer
- Interventions
- Mitomycin C; Cetuximab; Irinotecan.
- Participants
- 13
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger
“Due to the investigator leaving the institution, the study was terminated” - ACP for Local Application in Ankle Arthrodesis
“Study was terminated due to the untimely death of the investigator” - Therapeutic Exercise in Patients With Hemophilia
“The Study was terminated due to lack of funding for continuing” - Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
“Study discontinued due to futility.” - Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast
“Study discontinued due to lack of subject follow-up.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.